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BACKGROUND
Bococizumab, a humanized monoclonal antibody targeting proprotein convertase 
subtilisin–kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) 
cholesterol. However, the variability and durability of this effect are uncertain.
METHODS
We conducted six parallel, multinational lipid-lowering trials enrolling 4300 patients 
with hyperlipidemia who were randomly assigned to receive 150 mg of bocociz-
umab or placebo subcutaneously every 2 weeks and who were followed for up to 
12 months; 96% were receiving statin therapy at the time of enrollment. The pa-
tients were assessed for lipid changes over time, stratified according to the pres-
ence or absence of antidrug antibodies detected during the treatment period.
RESULTS
At 12 weeks, patients who received bococizumab had a reduction of 54.2% in the 
LDL cholesterol level from baseline, as compared with an increase of 1.0% among 
those who received placebo (absolute between-group difference, −55.2 percentage 
points). Significant between-group differences were also observed in total choles-
terol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) 
(P<0.001 for all comparisons). However, high-titer antidrug antibodies developed 
in a substantial proportion of the patients who received bococizumab, which 
markedly diminished the magnitude and durability of the reduction in LDL cho-
lesterol levels. In addition, among patients with no antidrug antibodies, there 
was wide variability in the reduction in LDL cholesterol levels at both 12 weeks 
and 52 weeks. Major cardiovascular events occurred in 57 patients (2.5%) who 
received bococizumab and in 55 (2.7%) who received placebo (hazard ratio, 0.96; 
95% confidence interval, 0.66 to 1.39; P = 0.83). The most common adverse event 
among patients who received bococizumab was injection-site reaction (12.7 per 
100 person-years).
CONCLUSIONS
In six multinational trials evaluating bococizumab, antidrug antibodies developed 
in a large proportion of the patients and significantly attenuated the lowering of 
LDL cholesterol levels. Wide variation in the relative reduction in cholesterol levels 
was also observed among patients in whom antidrug antibodies did not develop. 
(Funded by Pfizer; SPIRE ClinicalTrials.gov numbers, NCT01968954, NCT01968967, 
NCT01968980, NCT02100514, NCT02135029, and NCT02458287.)
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Reducing levels of low-density lipo-protein (LDL) cholesterol with statin ther-apy is a highly effective method for reduc-
ing cardiovascular risk.1 Trial data, observational 
studies, and genetic analyses indicate that further 
reductions in LDL cholesterol levels are likely to 
confer greater cardiovascular benefits.2-4 Yet, recent 
studies have shown wide variability in the individ-
ual response of patients to statin therapy in terms 
of the percent reduction in LDL cholesterol levels.5,6
Inhibitors of proprotein convertase subtilisin–
kexin type 9 (PCSK9) reduce plasma LDL choles-
terol levels by slowing PCSK9-mediated degra-
dation of the LDL receptor.7 Fully human 
monoclonal antibodies such as alirocumab and 
evolocumab that interfere with the LDL receptor–
binding domain of PCSK9 reduce circulating LDL 
cholesterol levels by approximately 60% and are 
promising agents for further reductions in car-
diovascular events.8,9
Bococizumab is a third monoclonal antibody 
targeting PCSK9 that, in a dose-finding study 
among statin-treated patients, lowered LDL choles-
terol levels by approximately 55 mg per deciliter 
(1.4 mmol per liter) from baseline when admin-
istered in a regimen of 150 mg subcutaneously 
every 2 weeks.10 Unlike alirocumab and evoloc-
umab, however, bococizumab is a humanized, 
rather than a fully human, therapeutic monoclo-
nal antibody with approximately 3% murine se-
quence remaining in the antigen-binding com-
plementarity-determining regions and as such 
may be more likely to induce the development of 
antidrug antibodies.11 As part of the bococizu-
mab development program, we conducted six 
parallel trials comparing 150 mg of bocociz-
umab subcutaneously every 2 weeks with placebo 
in patients with hyperlipidemia, including one 
trial in which some patients received atorvastatin 
instead of placebo and another in which some 
patients received 75 mg of bococizumab instead 
of 150 mg. All the patients were assessed for 
group and individual changes in lipid levels, 
durability of effect, safety, and incidence of car-
diovascular events.
Me thods
Trial Design and Oversight
The Studies of PCSK9 Inhibition and the Reduc-
tion of Vascular Events (SPIRE) program for the 
development of bococizumab consists of six 
parallel, multinational lipid-lowering studies and 
the SPIRE-1 and SPIRE-2 event-driven cardiovas-
cular outcome trials.12 The findings of the SPIRE 
lipid-lowering studies are reported here. The re-
sults of the SPIRE-1 and SPIRE-2 outcome trials 
are also reported elsewhere in the Journal.13
The protocols for each SPIRE study (available 
with the full text of this article at NEJM.org) were 
collaboratively designed by academic members of 
the SPIRE executive and steering committees and 
physician and statistician employees of the spon-
sor (Pfizer). Each protocol was approved at partici-
pating centers by the responsible institutional re-
view board or ethics committee, as applicable in 
the 35 countries involved in the SPIRE program. 
The sponsor supervised data collection. A single 
independent data and safety monitoring com-
mittee oversaw the trials. The first author and 
an independent academic statistician at Brigham 
and Women’s Hospital had full access to the 
trial databases and independent responsibility 
for generating trial analyses for publication, 
prepared the first draft of the manuscript, and 
made the decision to submit the manuscript for 
publication. All the authors critically reviewed the 
manuscript and vouch for the completeness and 
accuracy of the data and all analyses, and for the 
fidelity of the trials to the protocols.
Enrollment, Randomization, and Follow-up
The six studies in the lipid-lowering program 
included SPIRE-HR (which enrolled 711 patients 
with hyperlipidemia who were at high risk for 
cardiovascular events and who were receiving the 
maximum tolerated statin therapy), SPIRE-LDL 
(which enrolled 2139 patients with hyperlipidemia 
who had multiple cardiovascular risk factors and 
a directly measured LDL cholesterol level of ≥70 mg 
per deciliter [1.8 mmol per liter]), SPIRE-FH 
(which enrolled 370 patients with heterozygous 
familial hypercholesterolemia), SPIRE-LL (which 
enrolled 746 patients who had a directly measured 
LDL cholesterol level of ≥100 mg per deciliter 
[2.6 mmol per liter] while receiving statin ther-
apy and for whom additional lipid lowering was 
under consideration), SPIRE-SI (which enrolled 
184 patients with hyperlipidemia who were 
statin intolerant), and SPIRE-AI (which enrolled 
299 patients who had a directly measured LDL 
cholesterol level of ≥70 mg per deciliter and who 
received bococizumab with an autoinjector de-
vice). Detailed inclusion and exclusion criteria for 
the six SPIRE trials are provided in the Supple-
mentary Appendix, available at NEJM.org. All the 
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patients in the SPIRE trials provided written in-
formed consent.
In SPIRE-HR, SPIRE-LDL, and SPIRE-FH, eli-
gible patients underwent identical baseline lipid 
evaluations, were randomly assigned (in a 1:1 ratio) 
to receive either 150 mg of bococizumab subcuta-
neously every 2 weeks or placebo, and were then 
followed for 52 weeks; patients in SPIRE-LL were 
assigned to the same regimen but in a 2:1 ratio 
with placebo. In SPIRE-SI, eligible patients were 
randomly assigned in a 2:1:2 fashion to receive 
150 mg of bococizumab subcutaneously every 
2 weeks, 40 mg of atorvastatin orally daily, or 
matching doses of placebo and were followed 
for 6 months. In all these studies, the patients 
administered bococizumab or placebo themselves 
through subcutaneous injections. By contrast, in 
SPIRE-AI, eligible patients were randomly assigned 
to receive bococizumab or placebo that they ad-
ministered themselves with an autoinjector device 
and were followed for 12 weeks; in this study, pa-
tients were randomly assigned in a 2:2:1:1 ratio 
to receive 150 mg of bococizumab subcutaneously 
every 2 weeks, 75 mg of bococizu mab subcutane-
ously every 2 weeks, or matching doses of pla-
cebo. In total, 4449 patients were enrolled in the 
SPIRE lipid-lowering program, of whom 4263 were 
assigned to receive either 150 mg of bococizumab 
or placebo. For the analyses of clinical outcomes, 
the 37 patients in the SPIRE-SI study who were 
assigned to receive 40 mg of atorvastatin were 
included in the placebo group. Results for the re-
maining 149 patients in the SPIRE-AI study, who 
were assigned to receive 75 mg of bococizumab or 
placebo, are also reported here for completeness.
We performed the 12-month trials using an 
identical protocol that included a 4-week pre-
randomization screening period to verify eligi-
bility and ensure that patients were receiving the 
maximum tolerated statin dose. The SPIRE-SI 
protocol included a statin rechallenge group. In 
the 12-month trials, protocol-driven dose reduc-
tions in bococizumab were triggered by the ob-
servation of directly measured LDL cholesterol 
levels of 10 mg per deciliter (0.3 mmol per liter) 
or less on two consecutive visits, with sham dose 
modifications made in the placebo group to main-
tain the study blinding.12
Levels of antidrug antibodies, neutralizing 
antibodies, total PCSK9 levels, and bococizumab 
were measured with the use of validated assays 
(see the Methods section in the Supplementary 
Appendix).
Trial End Points
In all six SPIRE lipid-lowering trials, the primary 
end point was the percent change from baseline 
in fasting LDL cholesterol levels, as measured 
with a direct assay at week 12; in addition, the 
long-term persistence of any effects on the LDL 
cholesterol level was evaluated throughout the 
12-month follow-up period for the longer-term 
studies. Secondary end points were the percent 
changes in other lipid levels, lipoprotein(a), and 
high-sensitivity C-reactive protein at weeks 12 
and 52. All plasma samples were obtained after 
a minimum 10-hour fast, and all assays were 
performed at a core laboratory.
Statistical Analysis
We analyzed lipid-lowering data separately for 
each of the six SPIRE trials at 12 weeks and 52 
weeks and used a random-effects method in meta-
analyses of the combined data. In the combined 
analyses, we excluded the patients who had been 
assigned to receive atorvastatin in SPIRE-SI and 
those who were assigned to receive 75 mg of 
bococizumab or matching placebo in SPIRE-AI. 
In addition, we used waterfall plots to examine 
the individual biologic variability in LDL choles-
terol response to bococizumab at 12 weeks and 
52 weeks. Waterfall plots were limited to the 
patients who had reported taking either bocociz-
umab or placebo within 21 days before the lipid 
measurement. Analyses were stratified according 
to the presence or absence of detectable antidrug 
antibodies or neutralizing antibodies, with pa-
tients classified as positive if antibodies were de-
tected at any time during the trial. Analyses of 
the effects of neutralizing antibodies were limited 
to the two trials in which they were measured 
(SPIRE-HR and SPIRE-FH).
Per protocol, we examined safety events and 
the incidence of adjudicated cardiovascular events 
occurring after the time of randomization. The 
prespecified events that contributed to the latter 
analysis were the first occurrence of nonfatal 
myocardial infarction, nonfatal stroke, coronary 
revascularization, or cardiovascular death.12 For 
adverse events, weighted rate ratios are provided 
in which the weight for each study was calcu-
lated according to the inverse of the exposure 
time, similar to a Mantel–Haenszel method. We 
used a Cox proportional-hazards model to ana-
lyze cardiovascular outcomes on pooled data 
stratified according to trial. Further details with 
respect to the statistical analyses are provided in 
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the Methods section in the Supplementary Ap-
pendix.
R esult s
Trial Patients and Follow-up
The baseline clinical characteristics of the pa-
tients who were enrolled in each of the six trials 
are summarized in Table 1 and in Table S1 in the 
Supplementary Appendix. The mean age of the 
patients was 61 years, 42% were women, 53% had 
diabetes, 18% were current smokers, and 12% 
had a diagnosis of familial hypercholesterolemia. 
With the exception of those in the SPIRE-SI 
(statin-intolerant) trial, 99% of the patients were 
receiving statin therapy; of these patients, 86% 
were receiving high-intensity regimens, as de-
fined by recent clinical guidelines. Across the 
program, a total of 92 patients (2%) were lost to 
follow-up.
Treatment Responses at 12 Weeks and 52 Weeks
In each trial, directly measured LDL cholesterol 
levels at 12 weeks were significantly lower among 
the patients who received 150 mg of bocociz-
umab subcutaneously every 2 weeks than among 
those who received placebo (Table 2). At week 12, 
the mean percent change in LDL cholesterol was 
−54.2% among the patients who received boco-
cizumab and an increase of 1.0% among those 
who received placebo (between-group difference, 
−55.2 percentage points; 95% confidence inter-
val [CI], −57.9 to −52.6; P<0.001); the median 
between-group difference was −59.2 percentage 
points (95% CI, −60.5 to −57.8; P<0.001). The 
numbers of patients with missing data for LDL 
cholesterol levels in each SPIRE trial at 12 weeks 
and 52 weeks are provided in Table S2 and the 
results for each individual trial in Figure S1 and 
Tables S3 and S4 in the Supplementary Appendix.
Across the six trials, 150 mg of bococizumab 
Characteristic
SPIRE-HR 
(N = 711)
SPIRE-LDL 
(N = 2139)
SPIRE-FH 
(N = 370)
SPIRE-LL 
(N = 746)
SPIRE-SI 
(N = 184)
SPIRE-AI 
N = 299)
All Trials 
(N = 4449)
Age (yr) 61.3 62.0 56.1 61.6 63.9 60.0 61.3
Female sex (%) 37.4 40.6 41.9 44.2 53.8 45.8 41.7
Diabetes (%) 49.4 62.9 20.3 56.4 24.5 44.1 53.3
Hypertension (%) 84.0 82.6 51.9 77.5 70.1 74.2 78.3
Current smoking (%) 16.2 19.1 18.6 22.1 7.6 15.7 18.4
Familial hypercholesterolemia (%) 7.2 1.9 100.0 7.0 10.9 1.3 12.1
Statin use (%)
Any 100.0 99.7 99.5 99.9 0.0 100.0 99.8†
High-intensity‡ 91.6 93.5 94.9 64.7 0.0 62.2 86.0†
LDL cholesterol (mg/dl) 114.9 112.2 147.1 135.5 174.3 111.9 122.0
Total cholesterol (mg/dl) 187.5 184.7 224.0 210.0 256.2 179.0 195.2
Apolipoprotein B (mg/dl) 94.5 93.2 114.4 106.7 128.6 90.2 98.7
Non-HDL cholesterol (mg/dl) 138.6 136.6 174.5 161.4 204.1 129.7 146.5
Triglycerides (mg/dl)§ 138.0 147.4 123.5 168.3 165.5 119.5 145.0
Lipoprotein(a) (mg/dl)§ 22.9 21.0 28.8 23.3 13.9 NA 21.7
High-sensitivity C-reactive protein 
(mg/liter)§
1.6 2.0 0.9 2.2 NA NA 1.8
Loss to follow-up by study end (%)¶ 1.4 2.7 0.0 2.9 0.5 0.7 2.1
*  All the listed values are means unless otherwise indicated. Complete data with respect to individual study groups in each trial are provided 
in Table S1 in the Supplementary Appendix. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the 
values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, LDL low-density lipoprotein, and 
NA not available.
†  Total values for statin use do not include SPIRE-SI.
‡  High-intensity statin use was defined as a daily dose of at least 40 mg of atorvastatin, at least 20 mg of rosuvastatin, or at least 40 mg of 
simvastatin.
§  Values for normally distributed variables are means, and values for triglycerides, lipoprotein(a), and high-sensitivity C-reactive protein are medians.
¶  All the trials had 12 months of follow-up except SPIRE-SI (6 months) and SPIRE-AI (12 weeks).
Table 1. Clinical Characteristics of the Patients at Baseline and Loss to Follow-up in the Six Lipid-Lowering SPIRE Trials.*
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also had favorable effects at 12 weeks on other 
lipid levels, including between-group differences 
from placebo of −36.0 percentage points in total 
cholesterol, −49.5 percentage points in apolipo-
protein B, −50.2 percentage points in non–high-
density lipoprotein (HDL) cholesterol, −14.2 per-
centage points in triglycerides, −28.9 percentage 
points in lipoprotein(a), and 6.2 percentage points 
in HDL cholesterol (P<0.001 for all comparisons) 
(Table 2, and Figs. S2 through S7 in the Supple-
mentary Appendix). No significant effect was ob-
served with respect to high-sensitivity C-reactive 
protein (data not shown).
At 52 weeks, the magnitude of percent reduc-
tion in LDL cholesterol that could be attributed to 
bococizumab was attenuated in all 1-year SPIRE 
trials, so that the modeled average between-group 
difference from placebo in LDL cholesterol lower-
ing at 52 weeks was −42.5 percentage points 
(95% CI, −47.3 to −37.8). Similar attenuation was 
observed at 52 weeks for total cholesterol, apolipo-
protein B, non-HDL cholesterol, lipoprotein(a), HDL 
cholesterol, and triglycerides (Table 2, and Figs. S8 
through S16 in the Supplementary Appendix).
Antidrug Antibodies and Treatment Response
At 1 year, 48% of the patients who received boco-
cizumab had detectable antidrug antibodies; most 
of the antibodies developed after week 12. For the 
patients who received bococizumab and who were 
in the lowest third and middle third of maxi-
mum titers of antidrug antibodies (<1:1176), the 
observed mean change in the LDL cholesterol 
level at 52 weeks (−43.1%) was virtually identical 
to that observed among those who did not have 
detectable antidrug antibodies (−42.5%). However, 
at 52 weeks, among the 16% of the patients who 
received bococizumab and who had antidrug-
antibody titers in the top third of maximum titers 
(≥1:1176), the mean change in the LDL choles-
Lipid Fraction 
and Study Period No. of Patients Percent Change from Baseline
Between-Group Difference 
(95% CI)† P Value
Bococizumab Placebo
% percentage points
LDL cholesterol
12 wk 3969 −54.2 1.0 −55.2 (−57.9 to −52.6) <0.001
52 wk 3460 −40.4 2.1 −42.5 (−47.3 to −37.8) <0.001
Total cholesterol
12 wk 3981 −35.5 0.1 −36.0 (−37.6 to −34.4) <0.001
52 wk 3466 −27.4 −0.2 −27.1 (−30.4 to −23.7) <0.001
Apolipoprotein B
12 wk 3972 −49.6 0.3 −49.5 (−52.1 to −47.0) <0.001
52 wk 3456 −36.8 0.1 −37.3 (−40.8 to −33.8) <0.001
Non-HDL cholesterol
12 wk 3977 −49.7 0.3 −50.2 (−52.5 to −47.9) <0.001
52 wk 3463 −37.9 −0.2 −37.7 (−41.7 to −33.8) <0.001
HDL cholesterol
12 wk 3979 6.4 0.6 6.2 (4.7 to 7.6) <0.001
52 wk 3463 6.0 1.3 4.6 (3.3 to 5.9) <0.001
Triglycerides
12 wk 3982 −12.1 1.9 −14.2 (−16.8 to −11.6) <0.001
52 wk 3466 −11.0 −0.6 −10.9 (−13.7 to −8.2) <0.001
Lipoprotein(a)
12 wk 3821 −25.9 3.0 −28.9 (−32.0 to −25.8) <0.001
52 wk 3451 −16.4 3.7 −20.6 (−29.5 to −11.8) <0.001
*  All the listed analyses do not include data for the patients who were assigned to receive 40 mg of atorvastatin in SPIRE-SI and those who 
were assigned to receive 75 mg of bococizumab or placebo in SPIRE-AI.
†  The between-group difference is the difference between the patients who received bococizumab and those who received placebo. The per-
cent difference and the corresponding 95% confidence intervals (CIs) and P values were modeled from a meta-analysis of all pertinent SPIRE 
trials with the use of the DerSimonian–Laird approach.
Table 2. Percent Change from Baseline in Lipid Levels at 12 Weeks and 52 Weeks.*
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terol level was −30.7%. In the subgroup of pa-
tients with antidrug-antibody titers in the top 
10% (≥1:5674), the mean change in LDL choles-
terol level was −12.3% (Fig. 1A).
The patients with antidrug antibodies had 
titer-dependent attenuation in both total PCSK9 
response and plasma bococizumab levels (Fig. 
1B and 1C). Further characterization of the anti-
drug-antibody response showed that neutraliz-
ing antibodies developed in 29% of the patients 
who received bococizumab. The reduction in the 
LDL cholesterol level at 52 weeks was substan-
tially attenuated in the subgroups of patients 
who had increasing neutralizing-antibody titers, 
an effect that was seen as early as 4 weeks (Fig. 
1D, and Figs. S17 and S18 in the Supplementary 
Appendix).
Variation in Response at 12 Weeks and 52 Weeks
Although the average group effect of bocociz-
umab on LDL cholesterol levels at 12 weeks was 
large, waterfall plots showed wide variation 
among the patients, such that 4% had no reduc-
tion in LDL cholesterol levels, 28% had a reduc-
tion in LDL cholesterol levels of less than 50%, 
and 68% had a reduction of 50% or more (Fig. 
2A). By 52 weeks, among the patients with anti-
drug antibodies, only 52% maintained a reduc-
tion of 50% or more in LDL cholesterol levels 
(Fig. 2B). However, among the patients with no 
antidrug antibodies, there was also a wide varia-
tion in the individual response to bococizumab 
at 52 weeks (Fig. 2C). Wide variation in the re-
duction in LDL cholesterol levels among the pa-
tients was further observed in similar analyses 
stratified according to the antibody response at 
12 weeks and at 52 weeks, including among 
patients who did not have neutralizing antibod-
ies at 52 weeks (Figs. S19 through S22 in the 
Supplementary Appendix).
Adverse Outcomes and Clinical Events
The rates of adverse events that were categorized 
as serious were 11.3 per 100 person-years of 
exposure among the patients who received boco-
cizumab and 13.3 per 100 person-years among 
the patients who received placebo (Table 3). The 
rate of injection-site reactions was 12.7 per 100 
person-years among the patients who received 
bococizumab (of whom 68% had antidrug anti-
bodies); these rates did not progress over time 
and led to the discontinuation of bococizumab 
in less than 1% of the patients. Although ar-
thralgia was more common in the bococizumab 
group than in the placebo group, rates for other 
monitored events and for laboratory abnormali-
ties were similar in the two groups.
Major adverse cardiovascular events including 
coronary revascularization occurred in 57 pa-
tients (2.5%) who received bococizumab and in 
55 (2.7%) who received placebo (hazard ratio, 
0.96; 95% CI, 0.66 to 1.39; P = 0.83) (Table 3, and 
Fig. S23 in the Supplementary Appendix). The 
more restricted clinical end point of nonfatal 
myocardial infarction, nonfatal stroke, or car-
diovascular death was reported in 34 patients 
(1.5%) who received bococizumab and in 27 
(1.3%) who received placebo (hazard ratio, 1.16; 
95% CI, 0.70 to 1.94; P = 0.56) (Table 3, and Fig. 
S24 in the Supplementary Appendix).
Discussion
Therapeutic monoclonal antibodies targeting 
PCSK9 include those that are fully human (e.g., 
alirocumab and evolocumab) and those that are 
humanized (e.g., bococizumab). Although anti-
drug antibodies can develop in response to either 
Figure 1 (facing page). Effect of Antidrug Antibodies  
on the Durability of Low-Density Lipoprotein (LDL) 
Cholesterol Lowering and on Plasma Bococizumab  
and PCSK9 Levels.
Panel A shows the effect of generalized antidrug anti-
bodies (ADAs) on LDL cholesterol levels among the 
patients who received placebo and among those who 
received bococizumab, according to whether the pa-
tients were ADA-negative throughout the trial, had ADA 
titers in the lowest two thirds of maximum titers (<1:1176) 
during follow-up, had ADA titers in the highest third of 
titers (≥1:1176) during follow-up, or were in the sub-
group with ADA titers in the top 10% (≥1:5674). The 
light blue bars indicate prevalent rates of antibodies at 
each time point, and the dark blue bars the cumulative 
incidence of antibody positivity during follow-up. Panel B 
shows plasma bococizumab levels and Panel C total 
plasma proprotein convertase subtilisin–kexin type 9 
(PCSK9) levels over time, according to the ADA titer. 
Panel D shows the effect of the neutralizing antibody 
(NAb) titer on LDL cholesterol levels. Data are shown 
for the patients who received placebo and those who 
received bococizumab, according to whether the pa-
tients were NAb-negative throughout the trial, had NAb 
titers in the lowest two thirds of maximum titers (<1:26) 
during follow-up, had NAb titers in the highest third of 
titers (≥1:26) during follow-up, or had NAb titers in the 
top 10% (≥1:74). To convert the values for cholesterol 
to millimoles per liter, multiply by 0.02586.
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fully human or humanized monoclonal antibod-
ies, neither alirocumab nor evolocumab has been 
associated with clinically significant antibody 
production (see the letter by Roth et al., now pub-
lished in the Journal14). In addition, each of these 
agents has shown durable reductions in LDL 
cholesterol levels with prolonged treatment.8,9
As shown in this report of six parallel trials, 
bococizumab at a dose of 150 mg subcutane-
ously every 2 weeks reduced LDL cholesterol 
levels at 12 weeks by 55.2 percentage points as 
compared with placebo, with significant reduc-
tions in other atherogenic lipid fractions as well. 
However, this early benefit was substantially 
attenuated over time among the 16% of patients 
in whom high-titer anti–bococizumab antibod-
ies developed during the study. In such patients, 
the reduction from baseline in LDL cholesterol 
levels with bococizumab was only 31% at 52 
weeks (and only 12% among those with the very 
highest antibody titers). By contrast, for the pa-
tients in whom antidrug antibodies did not de-
velop, the observed reduction in LDL cholesterol 
levels at 52 weeks was 43%. Similar results were 
observed when only neutralizing antibodies to 
bococizumab were examined.
Given the observation in our data that the at-
tenuation of LDL cholesterol lowering was similar 
among patients with antidrug antibodies and 
those with neutralizing antibodies, it is reason-
able to assume (in the absence of experimental 
data) that most antidrug antibodies to bocociz-
umab are formed against the murine sequence 
located in or near the complementarity-determin-
ing regions responsible for PCSK9 binding. No 
clinical data are available regarding cross-reactivity 
to other PCSK9 inhibitors among the patients who 
received bococizumab in whom antidrug anti-
bodies developed and who were subsequently 
treated with either evolocumab or alirocumab. 
However, given the specificity of binding do-
mains, such effects are unlikely to occur.
Bococizumab immunogenicity influenced the 
rate of adverse event rates and perhaps clinical 
outcomes. Specifically, bococizumab was associ-
ated with a substantially higher rate of injection-
site reactions (12.7 per 100 person-years) than 
rates that were previously reported with either 
evolocumab or alirocumab. With regard to clin-
ical efficacy, we believe that the report of no 
significant reduction in major cardiovascular 
outcomes with bococizumab should be inter-
preted with caution, given the small number of 
events accrued and the brief exposure period. 
Nonetheless, despite similar caveats, prelimi-
nary reports of post hoc analyses of evolocumab 
and alirocumab have shown substantial and 
statistically significant reductions in vascular 
events with even smaller sample sizes.8,9
Beyond issues of reduced durability, our data 
also show that there was wide variation among 
the patients in the magnitude of LDL cholesterol 
response to bococizumab and that this variation 
was present as early as 12 weeks (largely before 
Figure 2. Variability in the Reduction in LDL Cholesterol Levels, According 
to the Presence or Absence of Antidrug Antibodies (ADAs).
Waterfall plots for individual patients who received bococizumab show the 
percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) 
and at 52 weeks among the patients in whom antidrug antibodies developed 
(Panel B) and among those in whom antidrug antibodies did not develop 
(Panel C). Data are limited to the patients who reported having received 
bococizumab in the 21 days before the measurement of LDL cholesterol.
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the detection of antidrug antibodies). Further-
more, wide individual variation in LDL choles-
terol response was observed at 52 weeks among 
patients who did not have an antidrug-antibody 
response. The clinical and genetic determinants 
of this variation are currently uncertain. How-
ever, these data show that the biologic response 
to bococizumab was not uniform and was dif-
ficult to predict for individual patients. Whether 
wide individual-level variation in LDL cholesterol 
reduction exists for other monoclonal antibodies 
targeting PCSK9 requires formal evaluation.15 
Variable
Bococizumab 
(N = 2377)
Placebo 
(N = 2058)
Incidence Rate Ratio 
(95% CI) P Value
number (rate per 100 patient-yr)
Adverse event
Any adverse event 1586 (147.4) 1325 (125.4) 1.17 (1.09 to 1.26) <0.001
Serious adverse event 241 (11.3) 255 (13.3) 0.85 (0.71 to 1.01) 0.08
Adverse event resulting in drug 
 discontinuation
115 (5.4) 98 (4.6) 1.17 (0.89 to 1.54) 0.26
Injection-site reaction 263 (12.7) 34 (1.6) 7.80 (5.42 to 11.22) <0.001
Myalgia 63 (2.9) 65 (3.0) 0.96 (0.68 to 1.37) 0.82
Arthralgia 97 (4.4) 65 (3.1) 1.41 (1.03 to 1.94) 0.03
Fatigue 43 (2.0) 53 (2.6) 0.76 (0.51 to 1.14) 0.18
Headache 68 (3.0) 62 (3.0) 0.99 (0.70 to 1.41) 0.95
Type 2 diabetes mellitus 56 (2.4) 46 (2.3) 1.08 (0.72 to 1.60) 0.71
Hypersensitivity reaction 3 (0.1) 4 (0.2) 0.72 (0.12 to 4.42) 0.72
Cataract 15 (0.6) 11 (0.6) 1.11 (0.49 to 2.55) 0.80
(N = 2377) (N = 2058)
Between-Group Difference 
(95% CI)†
number (percent)
Laboratory measurement
Aspartate aminotransferase ≥3× ULN  
after randomization
18 (0.8) 15 (0.7) 0.03 (−0.49 to 0.55) 0.91
Alanine aminotransferase ≥3× ULN  
after randomization
21 (0.9) 14 (0.7) 0.17 (−0.36 to 0.71) 0.53
Creatine kinase ≥3× ULN after  
randomization
37 (1.6) 32 (1.6) −0.02 (−0.79 to 0.75) 0.96
(N = 2283) (N = 2017) Hazard Ratio (95% CI)‡
number (percent)
Adjudicated clinical outcome
Nonfatal myocardial infarction 24 (1.1) 16 (0.8) 1.39 (0.74 to 2.64) 0.31
Nonfatal stroke 6 (0.3) 9 (0.4) 0.58 (0.20 to 1.65) 0.30
Unstable angina requiring urgent 
 revascularization
9 (0.4) 7 (0.3) 1.01 (0.37 to 2.73) 0.99
Any coronary revascularization 40 (1.8) 38 (1.9) 0.99 (0.63 to 1.54) 0.95
Cardiovascular death 4 (0.2) 2 (0.1) 1.99 (0.36 to 10.86) 0.42
MACE 34 (1.5) 27 (1.3) 1.16 (0.70 to 1.94) 0.56
MACE plus unstable angina requiring 
 revascularization
42 (1.8) 34 (1.7) 1.11 (0.70 to 1.75) 0.66
MACE plus any revascularization 57 (2.5) 55 (2.7) 0.96 (0.66 to 1.39) 0.83
*  Included in the analyses of adverse events and laboratory measurements are the 4435 patients who received at least one dose of bococi-
zumab or placebo. For the adjudicated clinical outcomes, included are the 4300 patients who underwent randomization to receive 150 mg 
of bococizumab or placebo or 40 mg of atorvastatin, regardless of whether they received the study drug. No adjudicated clinical outcomes 
occurred in the 75-mg dose group in the short-term SPIRE-AI study. MACE denotes major adverse cardiovascular event (defined as the first 
event of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), and ULN upper limit of the normal range.
†  The between-group difference is the difference between the patients who received bococizumab and those who received placebo.
‡  Hazard ratios were calculated with the use of a Cox proportional-hazards model stratified according to study.
Table 3. Adverse Events, Laboratory Measurements, and Prespecified Adjudicated Clinical Outcomes.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EAST ANGLIA on July 25, 2017. For personal use only. No other uses without permission. 
 Copyright © 2017 Massachusetts Medical Society. All rights reserved. 
n engl j med 376;16 nejm.org April 20, 20171526
Variability in Lipid Reduction with Bococizumab
Wide individual variation has previously been 
shown with statins, agents that share a common 
metabolic pathway.5,6
On November 1, 2016, the sponsor elected to 
discontinue further development of bocociz-
umab. This decision was based in part on the 
high rate of immunogenicity of the drug, as well 
as on the wide variation in the LDL cholesterol 
response among the patients.
In conclusion, in six parallel, randomized trials, 
bococizumab, a humanized monoclonal antibody 
that targets PCSK9, significantly reduced LDL 
cholesterol levels in most patients with hyper-
lipidemia at 12 weeks. However, bococizumab 
was commonly associated with the development 
of high-titer antidrug antibodies, an effect that 
resulted in substantive attenuation of LDL cho-
lesterol lowering at 52 weeks. Bococizumab was 
also associated with wide individual variation in 
LDL cholesterol lowering among the patients who 
were antibody-negative.
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